Hylton Mayer, MD
Ophthalmology · Chevy Chase, MDNPI 1174568695
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 47.8% of the total. Reporting peaked in 2019 at $26,821 and has fallen 97.7% since, to $612 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $221.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$25K
- AbbVie$15K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- NEW World Medical,inc.$3K
- Kala Pharmaceuticals, Inc.$1K
- Alcon$777
- plus $2K from 16 others
Across 73 payments — averaging $1326.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$91K
- AbbVie$6K
What the payments were for
- Consulting fees$13,61026%
- Speaking & faculty fees$28,28554%
- Travel & lodging$2,8996%
- Food & beverage$7,15314%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 21 | $24,833 |
| AbbVie(2 entities) | 72 | $14,726 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $5,197 |
| NEW World Medical,inc. | 12 | $2,872 |
| Kala Pharmaceuticals, Inc. | 4 | $1,367 |
| Alcon | 33 | $777 |
| Glaukos Corporation | 8 | $293 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $255 |
| Carl Zeiss Meditec, Inc. | 2 | $229 |
| Bausch & Lomb Americas Inc. | 11 | $229 |
| Novartis | 8 | $180 |
| Dompe US, Inc. | 2 | $164 |
| Rxsight Inc | 5 | $143 |
| Harrow Eye, LLC | 6 | $140 |
| Sight Sciences, Inc. | 5 | $136 |
| Eyepoint US, Inc. | 1 | $124 |
| Shire North American Group Inc | 1 | $123 |
| Thea Pharma Inc. | 4 | $91 |
| Amgen | 2 | $42 |
| Oyster Point Pharma, Inc. | 2 | $29 |
| Ivantis, Inc | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$24,490
- Rocklatan$24,490
- XEN$6,748
- VYZULTA$4,809
- Ahmed Glaucoma Valve$2,409
- Kahook Dual Blade$2,409
- EYSUVIS$1,300
- Streamline Surgical System$487
- Oxervate$139
- Clearpath$135
- Streamline$135
- DEXYCU$124
- XIIDRA$123
- IOLMaster 700$121
- QUATERA 700$121
- Tecnis IOL$120
How this compares
$51,981 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 76 | $48,705 |
| XiidraLifitegrast | 28 | $35,075 |
| RhopressaNetarsudil Mesylate | 35 | $21,598 |
| CombiganBrimonidine Tartrate/Timolol | 52 | $19,401 |
| Brinzolamide | 62 | $13,487 |
| VyzultaLatanoprostene Bunod | 17 | $11,513 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $9,987 |
| MieboPerfluorohexyloctane/Pf | 11 | $9,536 |
| Alphagan PBrimonidine Tartrate | 26 | $9,464 |
| Brimonidine Tartrate | 57 | $8,188 |
| Travatan ZTravoprost | 13 | $7,438 |
| Travoprost | 37 | $6,877 |
| Timolol MaleateTimolol Maleate/Pf | 19 | $6,390 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 28 | $4,316 |
| Prednisolone Acetate | 70 | $4,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $14,726 | $77,571154 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $229 | $56,12456 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $24,833 | $21,59835 claims |
| AlconSimbrinza | $777 | $9,98725 claims |
| NovartisTravatan Z | $180 | $7,43813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Chevy Chase
- Anand MantravadiChevy Chase$134K
- Deepika ShahChevy Chase$122K
- Thomas ClinchChevy Chase$104K
- Neil MartinChevy Chase$13K
- Kenneth SchorChevy Chase$12K
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.